We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has extended by three months the PDUFA-review date for Biogen Idec’s Plegridy, a drug candidate proposed to treat relapsing multiple sclerosis (MS), the drugmaker said Tuesday. Read More
The FDA has cleared Kips Bay Medical to expand its eMesh 1 feasibility trial to 27 patients and at 10 U.S. study sites, the Minneapolis devicemaker said Monday. Read More